Journal of the American Academy of Dermatology · 2026
Treatment of androgenetic alopecia in transgender people receiving testosterone therapy with sublingual minoxidil: A randomized, double-blind, placebo-controlled clinical trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tang Gia Toan, Leemaqz Shalem, Bhoyrul Bevin, Eisman Samantha, Kasprzak Michal, Sicinska Justyna, Sinclair Rodney, Cheung Ada S
Аннотация
BACKGROUND: Transgender people receiving testosterone may experience androgenetic alopecia. Treatments such as 5α-reductase inhibitors can interfere with masculinization.
OBJECTIVE: To assess the efficacy and safety of sublingual minoxidil in the treatment of mild androgenetic alopecia in transgender people receiving full-dose testosterone therapy.
METHODS: Participants were randomized 1:1 to receive either sublingual minoxidil 1.35 mg twice daily or placebo for 24 weeks; all received sublingual minoxidil 2.5 mg twice daily in an open-label extension phase. Tattoo-directed phototrichograms were performed. Co-primary endpoints were change in midfrontal and vertex target area hair count.
RESULTS: Forty-six participants were randomized (23 per arm). At Week 24, midfrontal target area hair count improved by +15.7 hairs/cm2 with minoxidil vs placebo (P = .03) but no difference observed in the vertex. In the exploratory open-label phase, net midfrontal improvement from Week 0 to 48 was +12.3 hairs/cm2 (P = .02) and significant gains in the vertex occurred by Week 48 compared to baseline (+37.9 hairs/cm2, P = .009). Minoxidil was well tolerated, with no effect on testosterone concentrations or serious adverse events.
LIMITATIONS: Mild baseline androgenetic alopecia may have reduced detection of change in global photographs and quality-of-life scores.
CONCLUSIONS: Sublingual minoxidil was an effective and well tolerated option in this population for promoting hair growth in trans people receiving testosterone.
OBJECTIVE: To assess the efficacy and safety of sublingual minoxidil in the treatment of mild androgenetic alopecia in transgender people receiving full-dose testosterone therapy.
METHODS: Participants were randomized 1:1 to receive either sublingual minoxidil 1.35 mg twice daily or placebo for 24 weeks; all received sublingual minoxidil 2.5 mg twice daily in an open-label extension phase. Tattoo-directed phototrichograms were performed. Co-primary endpoints were change in midfrontal and vertex target area hair count.
RESULTS: Forty-six participants were randomized (23 per arm). At Week 24, midfrontal target area hair count improved by +15.7 hairs/cm2 with minoxidil vs placebo (P = .03) but no difference observed in the vertex. In the exploratory open-label phase, net midfrontal improvement from Week 0 to 48 was +12.3 hairs/cm2 (P = .02) and significant gains in the vertex occurred by Week 48 compared to baseline (+37.9 hairs/cm2, P = .009). Minoxidil was well tolerated, with no effect on testosterone concentrations or serious adverse events.
LIMITATIONS: Mild baseline androgenetic alopecia may have reduced detection of change in global photographs and quality-of-life scores.
CONCLUSIONS: Sublingual minoxidil was an effective and well tolerated option in this population for promoting hair growth in trans people receiving testosterone.